<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01683422</url>
  </required_header>
  <id_info>
    <org_study_id>5110324</org_study_id>
    <nct_id>NCT01683422</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial will provide important data on the recurrence rates and patterns of failure&#xD;
      using state of the art target agent, chemotherapy and proton beam technology for patients&#xD;
      with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or greater&#xD;
      would be considered evidence of a regimen potentially worthy of further study as a new&#xD;
      treatment paradigm in one arm in a future phase III trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current trend toward using the biology of the disease as it becomes evident over a period&#xD;
      of chemotherapy to better select patients who will benefit from chemoradiotherapy (CRT) seems&#xD;
      to be the most pragmatic way to proceed, until we have a better means of predicting tumor&#xD;
      behavior and more active systemic agents. This has led to increased interest in treatment&#xD;
      regimens incorporating induction chemotherapy with target agent followed by CRT and&#xD;
      additional chemotherapy for diseases that carry a high risk for systemic relapse.&#xD;
&#xD;
      The PA.3 trial was the first phase III trial in advanced pancreatic cancer to show a survival&#xD;
      advantage with the addition of a second drug, in this case the oral Epidermal growth factor&#xD;
      receptor (EGFR) inhibitor Erlotinib to gemcitabine. The approval provides an important proof&#xD;
      of concept regarding the use of newer &quot;targeted&quot; therapies in pancreatic cancer 7. Proton&#xD;
      beam therapy may result in lower toxicity, enhanced efficacy and could contribute to improved&#xD;
      local control of patients with LAPC. The capecitabine and oxaliplatin ((CapOx)) regimen&#xD;
      utilized in this trial has been proven to be active in gemcitabine-pretreated patients with&#xD;
      advanced pancreatic cancer.&#xD;
&#xD;
      The current trial will provide important data on the recurrence rates and patterns of failure&#xD;
      using state of the art target agent, chemotherapy and proton beam technology for patients&#xD;
      with LPAC. A median survival of 10 months or greater would be considered evidence of a&#xD;
      regimen potentially worthy of further study as a new treatment paradigm in one arm in a&#xD;
      future phase III trial.&#xD;
&#xD;
      Patients with unresectable or borderline resectable non-metastatic adenocarcinoma of the&#xD;
      pancreas, as defined by 2012 National Comprehensive Cancer Network (NCCN) guidelines, were&#xD;
      included. Patients received neoadjuvant gemcitabine 1000 mg/m2 IV on days 1, 8, 15, 22, 29,&#xD;
      36, and 43 and erlotinib 100 mg by mouth every day for 1-43 days (GE). If there was no&#xD;
      evidence of metastatic disease after GE, then patients preceded with proton therapy to 50.4&#xD;
      Gy in 28 fractions with concurrent capecitabine 825 mg/m2 twice per day (PCT). This was&#xD;
      followed with maintenance oxaliplatin 130 mg/m2 on day 1 and capecitabine 1000 mg/m2 twice&#xD;
      per day on days 2 to 15 (CapOx) for 4 cycles. The primary study objective was 1-year overall&#xD;
      survival (OS). The benchmark was 43% 1-year survival as demonstrated in Radiation Therapy&#xD;
      Oncology Group (RTOG/NRG) 98- 12. The Kaplan-Meier method was used to estimate the one-year&#xD;
      OS and the median OS and progression-free survival (PFS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Updated chemotherapy regimens currently evaluated in clinical trials due to lack of progress in&#xD;
    treating this condition; analysis continues in the realm of patterns of failure and increasing&#xD;
    quality of life&#xD;
  </why_stopped>
  <start_date type="Actual">January 2, 2013</start_date>
  <completion_date type="Actual">February 19, 2019</completion_date>
  <primary_completion_date type="Actual">February 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year Survival Rate</measure>
    <time_frame>One year after treatment completed.</time_frame>
    <description>Subjects will be followed after treatment completed to determine length of survival rate. The primary study objective was 1-year overall survival (OS, failure: death due to any cause). The Kaplan-Meier method was used to estimate the one-year OS. Secondary Objectives were the frequency of serious adverse events, disease control rate and progression-free survival.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Proton Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43&#xD;
PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.&#xD;
Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed&#xD;
Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton, Gemcitabine, Erlotinib, Capecitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.&#xD;
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.</description>
    <arm_group_label>Proton Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation</intervention_name>
    <arm_group_label>Proton Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma&#xD;
             of the pancreas&#xD;
&#xD;
          -  The American Joint Committee on Cancer (AJCC) stage I-III with unresectable or&#xD;
             borderline unresectable disease as defined by NCCN guidelines&#xD;
&#xD;
          -  Radiological resectability is defined by the following criteria on abdominal imaging:&#xD;
&#xD;
               1. No evidence of tumor extension to the celiac axis, hepatic artery or superior&#xD;
                  mesenteric artery.&#xD;
&#xD;
               2. No evidence of tumor encasement or occlusion of the superior mesenteric vein&#xD;
                  (SMV) or the SMV/portal vein confluence&#xD;
&#xD;
               3. No evidence of visceral or peritoneal metastases&#xD;
&#xD;
          -  Borderline and Unresectable cases would be defined as those that do not meet the&#xD;
             criteria in section and also show no evidence of distant metastatic or intraperitoneal&#xD;
             disease.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of ≤ 2&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Adequate hematologic reserve, hepatic reserve and renal function&#xD;
&#xD;
          -  White Blood Cell (WBC) &gt; 2,000 cells/mm3&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) &gt; 1,500 cells/mm3&#xD;
&#xD;
          -  Platelets &gt; 100,000 cells/mm3&#xD;
&#xD;
          -  Serum bilirubin ≤ 2.5 mg/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥&#xD;
             30ml/min&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &lt; 3 times ULN&#xD;
&#xD;
          -  Aspartate transaminase (AST) &lt; 3 times ULN&#xD;
&#xD;
          -  Albumin &gt; 3.2 g/dl&#xD;
&#xD;
          -  Patient must sign study-specific informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AJCC stage IV with metastatic disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of &gt; 2&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  WBC &lt; 2,000 cells/mm3&#xD;
&#xD;
          -  ANC &lt; 1,500 cells/mm3&#xD;
&#xD;
          -  Platelets &gt; 100,000 cells/mm3&#xD;
&#xD;
          -  Serum bilirubin &gt; 2.5 mg/dL&#xD;
&#xD;
          -  Serum creatinine &gt; 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥&#xD;
             30ml/min&#xD;
&#xD;
          -  ALT &gt; 3 times ULN&#xD;
&#xD;
          -  AST &gt; 3 times ULN&#xD;
&#xD;
          -  Albumin &lt; 3.2 g/dl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>gyang@llu.edu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>August 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Gary Yang, MD</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01683422/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01683422/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proton Radiation</title>
          <description>Proton, Gemcitabine, Erlotinib, Capecitabine: Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.&#xD;
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.&#xD;
Proton Radiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Proton Radiation</title>
          <description>Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.&#xD;
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.&#xD;
Radiation: Proton Radiation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" lower_limit="47" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proton Radiation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>One-year Survival Rate</title>
        <description>Subjects will be followed after treatment completed to determine length of survival rate. The primary study objective was 1-year overall survival (OS, failure: death due to any cause). The Kaplan-Meier method was used to estimate the one-year OS. Secondary Objectives were the frequency of serious adverse events, disease control rate and progression-free survival.</description>
        <time_frame>One year after treatment completed.</time_frame>
        <population>The study enrolled 9 patients between January 2013 and March 2016, when the trial was closed due to poor accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Radiation</title>
            <description>Radiation: Proton, Gemcitabine, Erlotinib, Capecitabine Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.&#xD;
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.&#xD;
Radiation: Proton Radiation</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Survival Rate</title>
          <description>Subjects will be followed after treatment completed to determine length of survival rate. The primary study objective was 1-year overall survival (OS, failure: death due to any cause). The Kaplan-Meier method was used to estimate the one-year OS. Secondary Objectives were the frequency of serious adverse events, disease control rate and progression-free survival.</description>
          <population>The study enrolled 9 patients between January 2013 and March 2016, when the trial was closed due to poor accrual.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="31" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>In the RTOG 9812 (NCT00003591) for unresectable pancreatic cancer, a one-year survival rate of 43% was observed. There were 109 analyzable patients on NCT00003591 with 61 still at risk for death at one year. Using the method of Dixon and Simon, a sample size of 39 analyzable patients followed over 12 months will ensure at least 90% probability of detecting a minimum of 17% improvement in the one-year survival rate compared to NCT00003591 at the 0.10 significance level (with a one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The reported p-value was calculated, and is not attempting to indicate the threshold for statistical significance.</non_inferiority_desc>
            <p_value>0.1</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <desc>Patients with locally advanced pancreatic cancer--9 patients died due to recurrence of disease. Entered as serious Adverse Event (AE)</desc>
      <group_list>
        <group group_id="E1">
          <title>Proton Radiation</title>
          <description>Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.&#xD;
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>serious</sub_title>
                <description>metastatic disease</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Yang</name_or_title>
      <organization>Loma Linda University Health</organization>
      <phone>909 558 4000 ext 88056</phone>
      <email>gyang@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

